Voltage-gated calcium-channels and antiarrhythmic drug action

Cardiovascular Research

Volumn 45, Issue 1, 2000, Pages 43-51

  Grace, Andrew A ^a   Camm, A John ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antiarrhythmic agents; Atrial function; Ca channel; Impulse formation; Membrane potential; Ventricular arrhythmias; Ventricular function

Indexed keywords

AMLODIPINE; ANTIARRHYTHMIC AGENT; CALCIUM CHANNEL; DILTIAZEM; ENCAINIDE; FLECAINIDE; GALLOPAMIL; MIBEFRADIL; MORACIZINE; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; OUABAIN; VERAPAMIL;

ATRIOVENTRICULAR CONDUCTION; CHANNEL GATING; DRUG SENSITIVITY; ELECTROPHYSIOLOGY; HEART ARRHYTHMIA; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE ISCHEMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REPERFUSION; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; HEART DISEASES; HUMANS; MOLECULAR SEQUENCE DATA;

EID: 0033991101     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00306-5     Document Type: Review

References (102)

1. Triggle D.J. Mechanisms of action of calcium channel antagonists. Epstein M. Calcium antagonists in clinical medicine. 1997;1-26 Hanley & Belfus, Philadelphia.
2. Singh B.N. Controlling cardiac arrhythmias with calcium channel blockers. Podrid P.J., Kowey P.R. Cardiac arrhythmia. Mechanisms, diagnosis and management. 1995;466-478 Williams & Wilkins, Baltimore.
3. Kamp T.J., Zhou Z., Zhang S., Makielski J.C., January C.T. The pharmacology of T- and L-type calcium channels in the heart. Jalife J., Zipes D. Cardiac electrophysiology: From cell to bedside. 3rd ed. 2000;W.B. Saunders, Philadelphia.
4. Farshi R., Kistner D., Sarma J.S., Longmate J.A., Singh B.N. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol. 33:1999;304-310.
5. Akhtar M., Tchou P., Jazayeri M. Use of calcium channel entry blockers in the treatment of cardiac arrhythmias. Circulation. 80:(6 Suppl):1989;31-IV9.
6. Sandler G., Clayton G.A., Thornicroft S.G. Clinical evaluation of verapamil in angina pectoris. Br Med J. 3:(612):1968;224-227.
7. Szekeres L., Papp J.G. The discovery of antiarrhythmics. Parnham M.J., Bruinvels J. Discoveries in pharmacology. 1984;185-215 Elsevier Science Publishers, Amsterdam.
8. Schmid J.R., Hanna C. A comparison of the antiarrhythmic actions of two new synthetic compounds, iproveratril and MJ 1999, with quinidine and pronethalol. J Pharmacol Exp Ther. 156:(2):1967;331-338.
9. Singh B.N., Vaughan-Williams E.M. A fourth class of anti-dysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function. Cardiovasc Res. 6:(2):1972;109-119.
10. Singh B.N., Vaughan-Williams E.M. Local anaesthetic and antiarrhythmic actions of alprenolol relative to its effect on intracellular potentials and other properties of isolated cardiac muscle. Br J Pharmacol. 38:(4):1970;749-757.
11. Echt D.S., Liebson P.R., Mitchell L.B., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. New Engl J Med. 324:(12):1991;781-788.
12. Carmeliet E. Antiarrhythmic drugs and ion channels: have we made the connection? J Cardiovasc Electrophysiol. 10:(5):1999;755-759.
13. Schamroth L., Krikler D.M., Garrett C. Immediate effects of intravenous verapamil in cardiac arrhythmias. Br Med J. 1:(801):1972;660-662.
14. Spurrell R.A., Krikler D.M., Sowton E. Effects of verapamil on electrophysiological properties of anomalous atrioventricular connexion in Wolff-Parkinson-White syndrome. Br Heart J. 36:(3):1974;256-264.
15. Camm A.J., Garratt C.J. Adenosine and supraventricular tachycardia. New Engl J Med. 325:(23):1991;1621-1629.
16. Braunwald E. Mechanism of action of calcium-channel-blocking agents. New Engl J Med. 307:(26):1982;1618-1627.
17. Yusuf S. Calcium antagonists in coronary artery disease and hypertension. Time for re-evaluation? Circulation. 92:(5):1995;1079-1082.
18. Furberg C.D., Psaty B.M., Meyer J.V. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 92:(5):1995;1326-1331.
19. McMurray J., Murdoch D. Calcium-antagonist controversy: the long and short of it? Lancet. 349:(9052):1997;585-586.
20. Moser M. Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists and calcium channel blocking agents: a review of potential benefits and possible adverse reactions. J Am Coll Cardiol. 29:(7):1997;1414-1421.
21. Braun S., Boyko V., Behar S., et al. Calcium channel blocking agents and risk of cancer in patients with coronary heart disease. Bezafibrate Infarction Prevention (BIP) Study Research Group. J Am Coll Cardiol. 31:(4):1998;804-808.
22. Hockerman G.H., Peterson B.Z., Johnson B.D., Catterall W.A. Molecular determinants of drug binding and action on L-type calcium channels. Annu Rev Pharmacol Toxicol. 37:1997;361-396.
23. Goldstein S.A., Colatsky T.J. Ion channels: too complex for rational drug design? Neuron. 16:(5):1996;913-919.
24. Nattel S. Newer developments in the management of atrial fibrillation. Am Heart J. 130:(5):1995;1094-1106.
25. Camm A.J., Yap Y.G. What should we expect from the next generation of antiarrhythmic drugs? J Cardiovasc Electrophysiol. 10:(2):1999;307-317.
26. De Waard M., Gurnett C.A., Campbell K.P. Structural and functional diversity of voltage-activated calcium channels. Ion Channels. 4:1996;41-87.
27. 2+ release. Cardiovasc Res. 42:1999;339-360.
28. Mori Y., Mikala G., Varadi G., et al. Molecular pharmacology of voltage-dependent calcium channels. Jpn J Pharmacol. 72:(2):1996;83-109.
29. McDonald T.F., Pelzer S., Trautwein W., Pelzer D.J. Regulation and modulation of calcium channels in cardiac, skeletal, and smooth muscle cells. Physiol Rev. 74:(2):1994;365-507.
30. Vassort G., Alvarez J. Cardiac T-type calcium current: pharmacology and roles in cardiac tissues. J Cardiovasc Electrophysiol. 5:(4):1994;376-393.
31. Brogden R.N., Markham A. Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris. Drugs. 54:(5):1997;774-793.
32. Carmeliet E., Mubagwa K. Antiarrhythmic drugs and cardiac ion channels: mechanisms of action. Prog Biophys Mol Biol. 70:(1):1998;1-72.
33. Fleckenstein A. History of calcium antagonists. Circ Res. 52:(2 Pt 2):1983;I3-16.
34. Hering S., Aczel S., Kraus R.L., et al. Molecular mechanism of use-dependent calcium channel block by phenylalkylamines: role of inactivation. Proc Natl Acad Sci USA. 94:(24):1997;13323-13328.
35. 2+ channels. Trends Pharmacol Sci. 19:(3):1998;108-115.
36. Salata J.J., Brooks R.R. Pharmacology of azimilide dihydrochloride (NE-10064), a class III antiarrhythmic agent. Cardiovasc Drug Rev. 15:1997;137-156.
37. Kodama I., Kamiya K., Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res. 35:(1):1997;13-29.
38. Nademanee K., Singh B.N., Stevenson W.G., Weiss J.N. Amiodarone and post-MI patients. Circulation. 88:(2):1993;764-774.
39. Nishimura M., Follmer C.H., Singer D.H. Amiodarone blocks calcium current in single guinea pig ventricular myocytes. J Pharmacol Exp Ther. 251:(2):1989;650-659.
40. Nattel S., Talajic M., Quantz M., DeRoode M. Frequency-dependent effects of amiodarone on atrioventricular nodal function and slow-channel action potentials: evidence for calcium channel-blocking activity. Circulation. 76:(2):1987;442-449.
41. Fei L., Gill J.S., McKenna W.J., Camm A.J. Effects of propafenone on calcium currents in single ventricular myocytes of guinea-pig. Br J Pharmacol. 109:(1):1993;178-182.
42. 2+ current by propafenone in single myocytes isolated from the rabbit atrioventricular node. Br J Pharmacol. 121:(1):1997;7-14.
43. 2+ channel current in rat ventricular myocytes by terfenadine. Circ Res. 81:(2):1997;202-210.
44. Yatani A., Brown A.M. Rapid beta-adrenergic modulation of cardiac calcium channel currents by a fast G protein pathway. Science. 245:(4913):1989;71-74.
45. Hartzell H.C., Mery P.F., Fischmeister R., Szabo G. Sympathetic regulation of cardiac calcium current is due exclusively to cAMP-dependent phosphorylation. Nature. 351:(6327):1991;573-576.
46. 2+ current in frog ventricular myocytes. Br J Pharmacol. 121:(7):1997;1277-1286.
47. Antzelevitch C., Sicouri S. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol. 23:(1):1994;259-277.
48. Lubbe W.F., Podzuweit T., Opie L.H. Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors. J Am Coll Cardiol. 19:(7):1992;1622-1633.
49. Merillat J.C., Lakatta E.G., Hano O., Guarnieri T. Role of calcium and the calcium channel in the initiation and maintenance of ventricular fibrillation. Circ Res. 67:(5):1990;1115-1123.
50. Janse M.J., Opthof T., Kleber A.G. Animal models of cardiac arrhythmias. Cardiovasc Res. 39:(1):1998;165-177.
51. Vos M.A., Gorgels A.P., Leunissen J.D., et al. Further observations to confirm the arrhythmia mechanism-specific effects of flunarizine. J Cardiovasc Pharmacol. 19:(5):1992;682-690.
52. Billman G.E., Hamlin R.L. The effects of mibefradil, a novel calcium channel antagonist on ventricular arrhythmias induced by myocardial ischemia and programmed electrical stimulation. J Pharmacol Exp Ther. 277:(3):1996;1517-1526.
53. The Sicilian Gambit. Circulation 1991;84:1831-1851.
54. Altemose G.T., Buxton A.E. Idiopathic ventricular tachycardia. Annu Rev Med. 50:1999;159-177.
55. The search for novel antiarrhythmic strategies. Sicilian Gambit. Eur Heart J. 1998;19(8):1178-1196.
56. Lerman B.B., Stein K.M., Markowitz S.M. Mechanisms of idiopathic left ventricular tachycardia. J Cardiovasc Electrophysiol. 8:(5):1997;571-583.
57. Maseri A., Louis F. Bishop lecture. Role of coronary artery spasm in symptomatic and silent myocardial ischemia. J Am Coll Cardiol. 9:(2):1987;249-262.
58. McAlister F.A., Teo K.K. Antiarrhythmic therapies for the prevention of sudden cardiac death. Drugs. 54:(2):1997;235-252.
59. Cranefield P.F., Aronson R.S., Wit A.L. Effect of verapamil on the normal action potential and on a calcium-dependent slow response of canine cardiac Purkinje fibers. Circ Res. 34:(2):1974;204-213.
60. Wellens H.J., Tan S.L., Bar F.W., et al. Effect of verapamil studied by programmed electrical stimulation of the heart in patients with paroxysmal re-entrant supraventricular tachycardia. Br Heart J. 39:(10):1977;1058-1066.
61. Talajic M., Lemery R., Roy D., et al. Rate-dependent effects of diltiazem on human atrioventricular nodal properties. Circulation. 86:(3):1992;870-877.
62. January C.T., Fozzard H.A. Delayed afterdepolarizations in heart muscle: mechanisms and relevance. Pharmacol Rev. 40:(3):1988;219-227.
63. Nayebpour M., Nattel S. Pharmacologic response of cesium-induced ventricular tachyarrhythmias in anesthetized dogs. J Cardiovasc Pharmacol. 15:(4):1990;552-561.
64. Cosio F.G., Goicolea A., Lopez Gil M., Kallmeyer C., Barroso J.L. Suppression of Torsades de Pointes with verapamil in patients with atrio-ventricular block. Eur Heart J. 12:(5):1991;635-638.
65. Leenhardt A., Glaser E., Burguera M., et al. Short-coupled variant of torsade de pointes. A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias. Circulation. 89:(1):1994;206-215.
66. Hohnloser S.H., Klingenheben T., Singh B.N. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med. 121:(7):1994;529-535.
67. Vergara I., Wharton J.M. Ventricular tachycardia and fibrillation in normal hearts. Curr Opin Cardiol. 13:(1):1998;9-19.
68. Tomaselli G., Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res. 42:1999;270-283.
69. 2+ currents in compensated hypertrophy and heart failure. Cardiovasc Res. 37:(2):1998;300-311.
70. Hasenfuss G. Alterations of calcium-regulatory proteins in heart failure. Cardiovasc Res. 37:(2):1998;279-289.
71. Packer M. Calcium channel blockers in chronic heart failure. The risks of 'physiologically rational' therapy. Circulation. 82:(6):1990;2254-2257.
72. Mahon N., McKenna W.J. Calcium channel blockers in cardiac failure. Prog Cardiovasc Dis. 41:(3):1998;191-206.
73. Packer M., O'Connor C.M., Ghali J.K., et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. New Engl J Med. 335:(15):1996;1107-1114.
74. Reuter H. The dependence of slow inward current in Purkinje fibres on the extracellular calcium-concentration. J Physiol (London). 192:(2):1967;479-492.
75. Reuter H. Exchange of calcium ions in the mammalian myocardium. Mechanisms and physiological significance. Circ Res. 34:(5):1974;599-605.
76. Mikami A., Imoto K., Tanabe T., et al. Primary structure and functional expression of the cardiac dihydropyridine-sensitive calcium channel. Nature. 340:(6230):1989;230-233.
77. Lee K.S., Tsien R.W. Mechanism of calcium channel blockade by verapamil, D600, diltiazem and nitrendipine in single dialysed heart cells. Nature. 302:(5911):1983;790-794.
78. Johnson B.D., Hockerman G.H., Scheuer T., Catterall W.A. Distinct effects of mutations in transmembrane segment IVS6 on block of L-type calcium channels by structurally similar phenylalkylamines. Mol Pharmacol. 50:(5):1996;1388-1400.
79. Schulz R., Post H., Jalowy A., et al. Unique cardioprotective action of the new calcium antagonist mibefradil. Circulation. 99:(2):1999;305-311.
80. Reimer K.A., Califf R.M. Good news for experimental concept but bad news for clinically effective therapy. Circulation. 99:(2):1999;198-200.
81. + channels. J Pharmacol Exp Ther. 234:(1):1985;134-140.
82. + channels involved in long QT syndromes, are targets for calcium channel blockers. Mol Pharmacol. 54:(4):1998;695-703.
83. Zhang S., Zhou Z., Gong Q., Makielski J.C., January C.T. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res. 84:(9):1999;989-998.
84. Podrid P.J. Redefining the role of antiarrhythmic drugs. New Engl J Med. 340:(24):1999;1910-1912.
85. Stafford R.S., Robson D.C., Misra B., Ruskin J., Singer D.E. Rate control and sinus rhythm maintenance in atrial fibrillation: national trends in medication use, 1980-1996. Arch Intern Med. 158:(19):1998;2144-2148.
86. Bassett A.L., Chakko S., Epstein M. Are calcium antagonists proarrhythmic? J Hypertens. 15:(9):1997;915-923.
87. Hennekens C.H., Albert C.M., Godfried S.L., Gaziano J.M., Buring J.E. Adjunctive drug therapy of acute myocardial infarction - evidence from clinical trials. New Engl J Med. 335:(22):1996;1660-1667.
88. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II- DAVIT II). Am J Cardiol 1990;66(10):779-785.
89. Catterall W.A. Yeasty brew yields novel calcium channel inhibitor. Nat Biotechnol. 16:(10):1998;906.
90. Daoud E.G., Knight B.P., Weiss R., et al. Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation. 96:(5):1997;1542-1550.
91. Tieleman R.G., De Langen C., Van Gelder I.C., et al. Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation. 95:(7):1997;1945-1953.
92. Goette A., Honeycutt C., Langberg J.J. Electrical remodeling in atrial fibrillation. Time course and mechanisms. Circulation. 94:(11):1996;2968-2974.
93. Yu W.C., Chen S.A., Lee S.H., et al. Tachycardia-induced change of atrial refractory period in humans: rate dependency and effects of antiarrhythmic drugs. Circulation. 97:(23):1998;2331-2337.
94. Wijffels M.C., Kirchhof C.J., Dorland R., Allessie M.A. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goat. Circulation. 92:(7):1995;1954-1968.
95. Tieleman R.G., Van Gelder I.C., Crijns H.J., et al. Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol. 31:(1):1998;167-173.
96. Niggli E. Localized intracellular calcium signaling in muscle: calcium sparks and calcium quarks. Annu Rev Physiol. 61:1999;311-335.
97. Gomez A.M., Valdivia H.H., Cheng H., et al. Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. Science. 276:(5313):1997;800-806.
98. Yue D.T. Quenching the spark in the heart. Science. 276:(5313):1997;755-776.
99. Ehlers MD, Augustine GJ. Cell signalling. Calmodulin at the channel gate. Nature 1999;399(6732):105, 107-108.
100. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 1997;350(9089):1417-1424.
101. Stanton A.V. Calcium channel blockers. The jury is still out on whether they cause heart attacks and suicide. Br Med J. 316:(7143):1998;1471-1473.
102. Cutler J.A. Calcium-channel blockers for hypertension - uncertainty continues. New Engl J Med. 338:(10):1998;679-681.